Please try another search
Mycenax Biotech Inc. develops and manufactures biopharmaceutical products from mammalian and microbial cell lines in Taiwan, Europe, Asia, and the United States. The company develops monoclonal antibodies, bi-specific antibodies, fc-fusion proteins, recombinant proteins, peptides, protein conjugates (non-toxin), antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), as well as plasmids and DNA vaccines. It also provides process development solutions, including development of production cell lines, upstream and downstream process development, process scale-up, formulation development, and analytical methods; in-house analytical services; GMP manufacturing services, such as drug substance and products manufacturing, and cell banking; and manufacturing technologies. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
En-Tzn Liu | - | - | Director |
Chia-Ling Lin | - | - | Director |
Chun-Hong Chen | - | - | Director |
Kuo-Pin Kao | - | - | Independent Director |
Yu-Sheng Tsai | - | - | Independent Director |
Pei-Jiun Chen | - | 2022 | President CEO & Chairman |
Allen Y. Chao | 78 | 2022 | Independent Director |
Yi-hsin Lee | - | 2024 | Director |
Yoh Ito San | - | 2022 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review